

Dr. Reinhold Cohn  
1899-1973

Ilan Cohn  
PhD Biol.

David Gilat  
B.Sc. Chem., LL.B., Adv.

Jonathan J. Topper  
M.A. Elec. Eng.

Ehud Hausman  
M.Sc. Comp. Sci.

David de Vries  
B.Sc. Mech. Eng.

Ena Pugatsch  
M.Sc. Opt. Mech. Eng.

Tamar Gallily  
M.Sc. Biol.

Jonathan Patinkin  
M.Sc. Biochem.

Bossmat Gonen  
PhD Biol.

Simon Kay  
B.Sc. Ind. Eng.

Svetlana Shtadler  
M.Sc. Phys.

Ben Tsoungin  
PhD Biol. and Maths.

Shulamit Hirsch  
PhD Chem.

Yigal Fraenkel  
PhD Chem.

Tamar Morag-Sela  
M.Sc. Chem.

Ronit Barzik-Soffer  
LL.B., Adv.

Rotem Geva-Singer  
LL.B., Adv.

Michael Cohn  
PhD Patent Attorney  
Consultant

Israel Shachter  
B.Sc. EPA, Patent Attorney  
Consultant

Moshe Brody  
PhD Phys. Elec.  
Scientific Adviser

Shoshana Kessel  
Inventor

Gil Zecler  
CFO

Kimberly Lindy  
Executive Director

Reinhold Cohn House  
21 Ahad Ha'am St.  
Tel Aviv 65151 Israel

Postal Address:  
P.O.B. 4060 Tel Aviv  
61040 Israel  
Tel: + 972 3 7109333  
Fax: + 972 3 5606405  
+ 972 3 5663782

Jerusalem Office:  
Tel: + 972 2 6595570/1  
Fax: + 972 2 6529139

Caesarea Office:  
Tel/Fax: + 972 6627 4841

Website:  
www.cohnpatents.co.il  
e-Mail:  
info@cohnpatents.co.il

RCP  
&P  
Established 1934

Reinhold Cohn & Partners  
P a t e n t   A t t o r n e y s

09/555964

533 Rec'd PCT/PTO 07 JUN 2000

February 14, 2000

**FACSIMILE TRANSMISSION  
OF        TEN        PAGE(S)  
TO: 0049 89 2399-4465**

European Patent Office  
D-80298 Munich

Attention: Authorized Officer/Examiner Weijland, A.

Dear Sirs,

**Re:    Response to Written Opinion of September 30, 1999  
Our Ref; 114508-5.MM:BG (Please quote)**

In response to the Written Opinion of reference, enclosed are the following:

1. Amended claim pages Nos. 14-16.
2. Amended pages 2, 3, 8, 12 and 13 of the specification.

**1.    Claim Amendments:**

The claims as originally filed were amended in accordance with the Examiner's comments as follows:

- 1.1 Original Claim 1 has been restricted to use of the protein preparation for the new indication subject of the present invention and thus now reads clear of the subject matter of the Shinitzky *et al.*, publication referred to in the Written Opinion as D1.
- 1.2 Claims 2-5 correspond with original Claims 7-10 but the kits recited in these claims have been restricted for use in the diagnosis of schizophrenia by determining a DTH reaction following injection of the protein preparation. The kits recited in the above amended claims comprise, in addition to the peptide preparation also instructions for use and a chart or picture for guidance of the manner of scoring the DTH results. This amendment is supported by the description on page 8 lines 20-36 of the specification. These new claims read clear of the D1 publication.

